Lite Strategy (LITS) Net Cash Flow (2010 - 2026)
Lite Strategy (LITS) posted Net Cash Flow of -$1.2 million for Q1 2026, up 10.41% on a QoQ basis from -$1.4 million in Q4 2025, and up 62.84% year-over-year from -$745514.7 in Q1 2025.
Analysis
Lite Strategy (LITS) Net Cash Flow (2010 - 2026) Analysis & Trends
Lite Strategy has reported Net Cash Flow for 17 years, with the latest figure at -$1.2 million in Q1 2026.
- On a quarterly basis, Net Cash Flow rose 62.84% year-over-year to -$1.2 million in Q1 2026; TTM through Mar 2026 was -$12.9 million, a 171.41% decrease from a year earlier, with the FY2025 full-year figure at $14.3 million, up 208.37% from the prior year.
- Net Cash Flow was -$1.2 million for Q1 2026 at Lite Strategy, up from -$1.4 million in the prior quarter.
- The five-year high for Net Cash Flow was $16.8 million in Q4 2024, with the low at -$13.5 million in Q3 2023.
- Average Net Cash Flow over 5 years is -$294529.4, with a median of -$1.4 million recorded in 2025.
- The sharpest annual moves came in 2023 and 2024: Net Cash Flow tumbled 1145.08% in 2023, then surged 831.58% in 2024.
- Over 5 years, Net Cash Flow stood at -$3.7 million in 2022, then surged by 148.23% to $1.8 million in 2023, then soared by 831.58% to $16.8 million in 2024, then plunged by 108.07% to -$1.4 million in 2025, then gained by 10.41% to -$1.2 million in 2026.
- The last three Net Cash Flow figures came in at -$1.2 million (Q1 2026), -$1.4 million (Q4 2025), and -$7.9 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 1.95 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -4.43 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 652.90 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -504.30 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -183.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | -496,000.00 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -2.09 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -170.75 Mn |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - | -1.21 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -1.21 Mn |
| Dec 31, 2025 | -1.36 Mn |
| Sep 30, 2025 | -7.90 Mn |
| Jun 30, 2025 | -2.46 Mn |
| Mar 31, 2025 | -3.27 Mn |
| Dec 31, 2024 | 16.79 Mn |
| Sep 30, 2024 | 3.25 Mn |
| Jun 30, 2024 | 1.34 Mn |
| Mar 31, 2024 | -2.81 Mn |
| Dec 31, 2023 | 1.80 Mn |
| Sep 30, 2023 | -13.53 Mn |
| Jun 30, 2023 | 8.09 Mn |
| Mar 31, 2023 | -2.11 Mn |
| Dec 31, 2022 | -3.74 Mn |
| Sep 30, 2022 | -1.09 Mn |
| Jun 30, 2022 | 4.63 Mn |
| Mar 31, 2022 | -1.44 Mn |
| Dec 31, 2021 | -3.07 Mn |
| Sep 30, 2021 | 7.08 Mn |
| Jun 30, 2021 | -1.20 Mn |